Track topics on Twitter Track topics that are important to you
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented speed and scale.
Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim, where Lexicon Pharmaceuticals and GlaxoSmithKline have entered into licensing agreements with Nuevolution. In a 4 million budgeted project supported by the Danish Advanced Technology Fund, Nuevolution has initiated hit-to-lead optimization efforts. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution. Most recently, Nuevolution announced a joint venture with Cancer Research Technology (CRT), the commercial arm of Cancer Research UK.
Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolutions internal programs are focused on therapeutically important targets within inflammation and oncology.
Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences.
Phone: 45 70 20 09 87
Fax: 45 70 20 09 86
Edison Investment Research - Pharmaceutical & healthcare - Nuevolution: Nuevolution’s 2017 was defined by internal progress of the RORγt inhibitor and BET-BD1 programmes (expected to be cl...
Edison Investment Research - Pharmaceutical & healthcare - Nuevolution: July to September 2017 results highlight the continued progression of Nuevolution into a clinical company. Ongoing partnerships ...
The program that has been licensed to Janssen Biotech relate to a disease target in the therapeutic area of anti-infectives. Nuevolution will initially receive a Read more...
Edison Investment Research Limited 15-March-2018 / 15:12 GMT/BST London, UK, 28 February 2018 Edison issues outlook on Nuevolution (NUEV) Nuevolution's 2017 was defined by internal progress...
SummaryNuevolution A/S Nuevolution, a subsidiary of Nuevolution AB, is a biopharmaceutical company that develops treatments for cancer and chronic inflammatory diseases. It focuses on developing drugs...
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven...
We have published hundreds of Nuevolution A/S news stories on BioPortfolio along with dozens of Nuevolution A/S Clinical Trials and PubMed Articles about Nuevolution A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nuevolution A/S Companies in our database. You can also find out about relevant Nuevolution A/S Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...